A practical approach to communicating benefit-risk decisions of medicines to stakeholders.

J Leong; S  Walker; Mir-Saeed Shayegan Salek

doi:10.3389/fphar.2015.00099

A practical approach to communicating benefit-risk decisions of medicines to stakeholders.

J Leong, S Walker, Mir-Saeed Shayegan Salek

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

15 Downloads (Pure)

Abstract

Purpose: The importance of a framework for a systematic structured assessment of the benefits and risks has been established, but in addition, it is necessary that the benefit-risk decisions and the processes to derive those decisions are documented and communicated to various stakeholders for accountability. Hence there is now a need to find appropriate tools to enhance communication between regulators and other stakeholders, in a manner that would uphold transparency, consistency and standards.
Methods: A retrospective, non-comparative study was conducted to determine
the applicability and practicality of a summary template in documenting benefit-risk assessment and communicating benefit-risk balance and conclusions for reviewers to other stakeholders. The benefit-risk (BR) Summary Template and its User Manual was evaluated by 12 reviewers within a regulatory agency in Singapore, the Health Sciences Authority (HSA).
Results: The BR Summary Template was found to be adequate in documenting
benefits, risks, relevant summaries and conclusions, while the User Manual was useful in guiding the reviewer in completing the template. The BR Summary Template was also considered a useful tool for communicating benefit-risk decisions to a variety of stakeholders.
Conclusions: The use of a template may be of value for the communicating benefit-risk assessment of medicines to stakeholders.

Original language	English
Article number	99
Pages (from-to)	1-9
Number of pages	9
Journal	Frontiers in Pharmacology
Volume	6
DOIs	https://doi.org/10.3389/fphar.2015.00099
Publication status	Published - 11 Jun 2015

Access to Document

10.3389/fphar.2015.00099Licence: Unspecified

fphar-06-00099
© 2015 Leong, Walker and Salek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Final published version, 1.57 MBLicence: CC BY

Cite this

@article{b8a25e48ad5344b8967bdd37afa2bb71,

title = "A practical approach to communicating benefit-risk decisions of medicines to stakeholders.",

abstract = "Purpose: The importance of a framework for a systematic structured assessment of the benefits and risks has been established, but in addition, it is necessary that the benefit-risk decisions and the processes to derive those decisions are documented and communicated to various stakeholders for accountability. Hence there is now a need to find appropriate tools to enhance communication between regulators and other stakeholders, in a manner that would uphold transparency, consistency and standards.Methods: A retrospective, non-comparative study was conducted to determinethe applicability and practicality of a summary template in documenting benefit-risk assessment and communicating benefit-risk balance and conclusions for reviewers to other stakeholders. The benefit-risk (BR) Summary Template and its User Manual was evaluated by 12 reviewers within a regulatory agency in Singapore, the Health Sciences Authority (HSA).Results: The BR Summary Template was found to be adequate in documentingbenefits, risks, relevant summaries and conclusions, while the User Manual was useful in guiding the reviewer in completing the template. The BR Summary Template was also considered a useful tool for communicating benefit-risk decisions to a variety of stakeholders.Conclusions: The use of a template may be of value for the communicating benefit-risk assessment of medicines to stakeholders.",

author = "J Leong and S Walker and Salek, {Mir-Saeed Shayegan}",

note = "{\textcopyright} 2015 Leong, Walker and Salek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.",

year = "2015",

month = jun,

day = "11",

doi = "10.3389/fphar.2015.00099",

language = "English",

volume = "6",

pages = "1--9",

journal = "Frontiers in Pharmacology",

issn = "1663-9812",

publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - A practical approach to communicating benefit-risk decisions of medicines to stakeholders.

AU - Leong, J

AU - Walker, S

AU - Salek, Mir-Saeed Shayegan

N1 - © 2015 Leong, Walker and Salek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PY - 2015/6/11

Y1 - 2015/6/11

N2 - Purpose: The importance of a framework for a systematic structured assessment of the benefits and risks has been established, but in addition, it is necessary that the benefit-risk decisions and the processes to derive those decisions are documented and communicated to various stakeholders for accountability. Hence there is now a need to find appropriate tools to enhance communication between regulators and other stakeholders, in a manner that would uphold transparency, consistency and standards.Methods: A retrospective, non-comparative study was conducted to determinethe applicability and practicality of a summary template in documenting benefit-risk assessment and communicating benefit-risk balance and conclusions for reviewers to other stakeholders. The benefit-risk (BR) Summary Template and its User Manual was evaluated by 12 reviewers within a regulatory agency in Singapore, the Health Sciences Authority (HSA).Results: The BR Summary Template was found to be adequate in documentingbenefits, risks, relevant summaries and conclusions, while the User Manual was useful in guiding the reviewer in completing the template. The BR Summary Template was also considered a useful tool for communicating benefit-risk decisions to a variety of stakeholders.Conclusions: The use of a template may be of value for the communicating benefit-risk assessment of medicines to stakeholders.

AB - Purpose: The importance of a framework for a systematic structured assessment of the benefits and risks has been established, but in addition, it is necessary that the benefit-risk decisions and the processes to derive those decisions are documented and communicated to various stakeholders for accountability. Hence there is now a need to find appropriate tools to enhance communication between regulators and other stakeholders, in a manner that would uphold transparency, consistency and standards.Methods: A retrospective, non-comparative study was conducted to determinethe applicability and practicality of a summary template in documenting benefit-risk assessment and communicating benefit-risk balance and conclusions for reviewers to other stakeholders. The benefit-risk (BR) Summary Template and its User Manual was evaluated by 12 reviewers within a regulatory agency in Singapore, the Health Sciences Authority (HSA).Results: The BR Summary Template was found to be adequate in documentingbenefits, risks, relevant summaries and conclusions, while the User Manual was useful in guiding the reviewer in completing the template. The BR Summary Template was also considered a useful tool for communicating benefit-risk decisions to a variety of stakeholders.Conclusions: The use of a template may be of value for the communicating benefit-risk assessment of medicines to stakeholders.

U2 - 10.3389/fphar.2015.00099

DO - 10.3389/fphar.2015.00099

M3 - Article

SN - 1663-9812

VL - 6

SP - 1

EP - 9

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

M1 - 99

ER -

A practical approach to communicating benefit-risk decisions of medicines to stakeholders.

Abstract

Access to Document

Fingerprint

Cite this